Impact of pretransplant comorbidities on alemtuzumab-based reduced-intensity conditioning allogeneic hematopoietic SCT for patients with high-risk myelodysplastic syndrome and AML (Q84574792)
Jump to navigation
Jump to search
scientific article published on 21 September 2009
Language | Label | Description | Also known as |
---|---|---|---|
English | Impact of pretransplant comorbidities on alemtuzumab-based reduced-intensity conditioning allogeneic hematopoietic SCT for patients with high-risk myelodysplastic syndrome and AML |
scientific article published on 21 September 2009 |
Statements
Impact of pretransplant comorbidities on alemtuzumab-based reduced-intensity conditioning allogeneic hematopoietic SCT for patients with high-risk myelodysplastic syndrome and AML (English)
Z Y Lim
W Ingram
R Brand
A Ho
M Kenyon
J Marsh
21 September 2009